Institutional members access full text with Ovid®

Share this article on:

Successful Treatment of Osteomyelitis From Methicillin-Resistant Staphylococcus Aureus With Ceftaroline

Watkins, Richard R. MD, MS, FACP

Infectious Diseases in Clinical Practice: January 2013 - Volume 21 - Issue 1 - p 48–49
doi: 10.1097/IPC.0b013e31825b2110
Case Reports

Osteomyelitis due to methicillin-resistant Staphylococcus aureus (MRSA) is a challenging illness to treat because of limited antibiotic options. Ceftaroline is a novel cephalosporin with activity against MRSA. It is currently approved for the treatment of adults with community-acquired pneumonia (but not from MRSA) and bacterial skin and skin structure infections. This case report describes a patient with osteomyelitis from MRSA cured with ceftaroline.

From the Division of Infectious Diseases, Akron General Medical Center, Akron; and Department of Internal Medicine, Northeast Ohio Medical University. Rootstown, OH.

Correspondence to: Richard R. Watkins, MD, MS, FACP, Division of Infectious Diseases, Akron General Medical Center, Akron, OH. E-mail:

The author has no funding or conflicts of interest to disclose.

© 2013 Lippincott Williams & Wilkins, Inc.